ストックスクリーナーアプリを入手
30.39
1.37%
0.41
アフターアワーズ：
30.39
Axogen Inc (AXGN) 最新ニュース
Is Axogen Stock Built to Withstand More Downside? - Trefis
Can Axogen Stock Recover If Markets Fall? - Trefis
Leerink Partners raises AxoGen stock price target to $40 on BLA approval - Investing.com Canada
Insider Sell: Marc Began Sells Shares of Axogen Inc (AXGN) - GuruFocus
Trade Alert: President Of Axogen Michael Dale Has Sold Stock - simplywall.st
Armistice Capital LLC Boosts Holdings in AxoGen, Inc. $AXGN - MarketBeat
Michael Dale Sells 61,463 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat
Paul Thomas Sells 21,399 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat
John Johnson Sells 21,686 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat
AxoGen (NASDAQ:AXGN) CFO Sells $454,053.72 in Stock - MarketBeat
Insider Sell: Paul Thomas Sells 21,399 Shares of Axogen Inc (AXG - GuruFocus
Axogen Insider Sold Shares Worth $1,390,393, According to a Recent SEC Filing - marketscreener.com
Axogen Insider Sold Shares Worth $633,710, According to a Recent SEC Filing - marketscreener.com
Legal & General Group Plc Purchases 83,175 Shares of AxoGen, Inc. $AXGN - MarketBeat
CFO Hartley Files To Sell 14,387 Of Axogen Inc [AXGN] - TradingView
H.C. Wainwright raises AxoGen stock price target to $39 after FDA approval - Investing.com Nigeria
AxoGen (NASDAQ:AXGN) Trading Down 4.7%What's Next? - MarketBeat
H.C. Wainwright raises AxoGen stock price target to $39 after FDA approval By Investing.com - Investing.com South Africa
(AXGN) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
AxoGen approves new CFO compensation and agreement - MSN
Prudential Financial Inc. Trims Stake in AxoGen, Inc. $AXGN - MarketBeat
Axogen (AXGN): Reassessing Valuation After FDA Biologics License Approval for AVANCE - Sahm
Axogen (AXGN) Price Target Increased by 18.26% to 34.58 - Nasdaq
AxoGen Secures FDA Approval for Avance Nerve Scaffold - The Globe and Mail
Canaccord Genuity Maintains Axogen (AXGN) Buy Recommendation - Nasdaq
AxoGen Approves New CFO Compensation and Agreement - TipRanks
AXGN: Canaccord Genuity Raises Price Target to $37, Maintains Bu - GuruFocus
AXGN Sees Enhanced Price Target by HC Wainwright & Co. Analyst Y - GuruFocus
Three Stocks Estimated To Be Trading Below Intrinsic Value In December 2025 - simplywall.st
AxoGen (NASDAQ:AXGN) Shares Gap UpHere's What Happened - MarketBeat
AxoGen stock price target raised to $37 from $27 at Canaccord Genuity - Investing.com Nigeria
AxoGen stock price target raised to $37 from $27 at Canaccord Genuity By Investing.com - Investing.com South Africa
AxoGen, Inc. $AXGN Shares Sold by Panagora Asset Management Inc. - MarketBeat
Will Axogen Inc. stock maintain growth storyWeekly Trend Summary & Real-Time Stock Price Movement Reports - Newser
Jefferies Raises Axogen (AXGN) Price Target to $36, Maintains Bu - GuruFocus
Jefferies Maintains Axogen (AXGN) Buy Recommendation - Nasdaq
AXGN: Lake Street Maintains "Buy" Rating and Raises Price Target to $40.00 | AXGN Stock News - GuruFocus
Why Is Axogen Stock Soaring Thursday?Axogen (NASDAQ:AXGN) - Benzinga
AxoGen stock price target raised to $36 from $27 at Raymond James By Investing.com - Investing.com South Africa
AxoGen stock price target raised to $36 from $27 at Raymond James - Investing.com Nigeria
AxoGen stock rises as Mizuho reiterates Outperform on BLA approval By Investing.com - Investing.com Nigeria
Why Is AXGN Stock Rising Today? - Stocktwits
Axogen's Avance secures FDA approval for nerve repair - BioWorld MedTech
FDA approves Axogen's nerve repair graft - Reuters
AxoGen stock rises as Mizuho reiterates Outperform on BLA approval - Investing.com
Jefferies raises AxoGen stock price target to $36 on Avance BLA approval - Investing.com Nigeria
Jefferies raises AxoGen stock price target to $36 on Avance BLA approval By Investing.com - Investing.com South Africa
Axogen, Inc. (AXGN) Stock: FDA Approval Boosts Avance as a Leading Nerve Repair Solution - parameter.io
Mizuho Begins Coverage on AxoGen (NASDAQ:AXGN) - MarketBeat
FDA Biologic Approval For AVANCE Might Change The Case For Investing In Axogen (AXGN) - simplywall.st
Axogen stock soars after FDA approval for nerve repair product By Investing.com - Investing.com South Africa
Axogen stock soars after FDA approval for nerve repair product - Investing.com India
0.52%
0.28%
大文字化:
|
ボリューム (24 時間):